For example, in non-small cell lung cancer (NSCLC), a gefitinib resistance-conferring mutation in EGFR (T790M) has been identified in the pre-treatment tumor or circulating tumor cells (Inukai et al, 2006; Maheswaran et al, 2008; Su et al, 2012b). This evidence concerns the gene EGFR and neoplasm.